Dr. Reddy’s Laboratories has announced the launch of Obeda®, India’s first DCGI-approved semaglutide injection for Type 2 Diabetes. This launch marks Dr. Reddy’s Day-1 entry into the GLP-1 receptor agonists therapy space, showcasing its readiness to serve patients in India.
In a head-to-head Phase-III clinical study involving 312 participants, Obeda® demonstrated non-inferior efficacy and a safety profile comparable to the innovator drug. The study showed similar glycaemic reduction, fasting glucose control, and therapeutic glycaemic response, with no anti-drug antibodies detected.
Obeda® is available in 2 mg and 4 mg strengths, packaged in a pre-filled, disposable pen for subcutaneous, once-a-week administration. Each pen delivers a minimum of 4 weekly doses, with a monthly cost of ₹4,200 for both strengths.
Dr. Reddy’s aims to introduce generic semaglutide in several countries, subject to regulatory approval, as part of its phase-1 launch. The company is building a full-breadth GLP-1 portfolio for multiple metabolic disorders, including diabetes and obesity.
Erez Israeli, CEO of Dr. Reddy’s, stated that the launch reflects the company’s capabilities in complex product development and peptide science. M.V. Ramana, CEO of Branded Markets (India and Emerging Markets), highlighted the importance of the launch in expanding access to advanced therapies in India.
Dr. Reddy’s has also developed SemaKare™, a patient support programme that includes a digital app offering onboarding guidance, injection training, and therapy-adherence monitoring. Additionally, the company plans to set up metabolic centres of excellence across India to advance diabetes treatment and patient care.
Dr. Reddy’s Obeda® is a prescription-based drug, and patients are advised to consult their doctors for more details.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).